Stoke Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	205.63	36.56	8.78	12.41	-	-
Revenue Growth (YoY)	1128.17%	316.34%	-29.22%	-	-	-
Gross Profit	205.63	36.56	8.78	12.41	-	-
Selling, General & Admin	58.79	48.79	41.32	38.92	31.9	20.85
Research & Development	119.65	89.13	82.23	77.84	54.17	32.2
Operating Expenses	178.44	137.93	123.55	116.76	86.07	53.04
Operating Income	27.2	-101.37	-114.77	-104.36	-86.07	-53.04
Interest & Investment Income	13.11	12.64	9.91	3.12	0.12	0.7
Other Non Operating Income (Expenses)	0.26	-0.25	0.17	0.17	0.14	0.1
Pretax Income	40.57	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income	40.57	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income to Common	40.57	-88.98	-104.7	-101.07	-85.81	-52.24
Shares Outstanding (Basic)	58	54	44	39	37	33
Shares Outstanding (Diluted)	60	54	44	39	37	33
Shares Change (YoY)	16.83%	22.76%	13.11%	5.87%	9.71%	86.34%
EPS (Basic)	0.70	-1.65	-2.38	-2.60	-2.34	-1.56
EPS (Diluted)	0.68	-1.65	-2.38	-2.60	-2.34	-1.56
Free Cash Flow	52.37	-87.05	-82.68	-35.83	-68.11	-43.27
Free Cash Flow Per Share	0.88	-1.61	-1.88	-0.92	-1.85	-1.29
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	13.23%	-277.31%	-1307.21%	-841.24%	-	-
Profit Margin	19.73%	-243.42%	-1192.47%	-814.73%	-	-
Free Cash Flow Margin	25.47%	-238.15%	-941.72%	-288.82%	-	-
EBITDA	29.09	-99.2	-112.3	-102.81	-85.09	-52.16
EBITDA Margin	14.14%	-271.36%	-	-	-	-
D&A For EBITDA	1.89	2.18	2.47	1.55	0.97	0.89
EBIT	27.2	-101.37	-114.77	-104.36	-86.07	-53.04
EBIT Margin	13.23%	-277.31%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.